Biotech | April 08, 2022
Essent Biologics launches Wharton's jelly-derived human mesenchymal stromal cells
Essent continues to broaden its highly characterized, low passage primary cell catalog
Essent continues to broaden its highly characterized, low passage primary cell catalog
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa Capsules of Boehringer lngelheim
BioFluidica LiquidScan harnesses the power of microfluidics
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
Drones will be used in the Gurugram and Mumbai region to transport pathology samples
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
Subscribe To Our Newsletter & Stay Updated
